Apitope

company

About

Apitope is a European biotech company

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
€10M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2002
Number Of Employee
11 - 50
Operating Status
Active

Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€22M
Apitope has raised a total of €22M in funding over 2 rounds. Their latest funding was raised on Sep 29, 2015 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 29, 2015 Series B €12M 1 Detail
Oct 30, 2008 Series A €10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Apitope is funded by 2 investors. Wyvern Seed Fund and Vinnof are the most recent investors.
Investor Name Lead Investor Funding Round
Wyvern Seed Fund Series B
Vinnof Series A